Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 100 #1
TickerUFPI [NASD]
CompanyUniversal Forest Products Inc.
CountryUSA
IndustryGeneral Building Materials
Market Cap1.00BEPS (ttm)2.80
P/E17.83EPS this Y77.70%
Forward P/E14.08EPS next Y20.78%
PEG1.78EPS past 5Y56.40%
P/S0.39EPS next 5Y10.00%
P/B1.44EPS Q/Q37.10%
Dividend0.84%Sales Q/Q9.50%
Insider Own0.30%Inst Own82.00%
Insider Trans57.58%Inst Trans0.30%
Short Float2.79%EarningsOct 15/a
Analyst Recom2.00Target Price55.00
Avg Volume79.12K52W Range40.70 - 58.27
29-Oct-14 04:36PMUNIVERSAL FOREST PRODUCTS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
28-Oct-14 11:50AMIndependent Bank Corporation Announces Appointment Of Matthew J. Missad To Its Board Of Directors PR Newswire
24-Oct-14 07:45AMAmira Nature Foods, Avon Products, Universal Forest Products, Bluelinx Holdings and Boise Cascade highlighted as Zacks Bull and Bear of the Day Zacks
23-Oct-14 01:20PMUniversal Forest Poised for Long-Term Growth, Risks Prevail Zacks
22-Oct-14 01:04PMUNIVERSAL FOREST PRODUCTS INC Financials EDGAR Online Financials
16-Oct-14 09:50AMUniversal Forest Products Lags Q3 Earnings, Improves Y/Y Zacks
16-Oct-14 08:30AMUniversal Forest Products Inc Earnings Call scheduled for 8:30 am ET today CCBN
15-Oct-14 04:57PMUNIVERSAL FOREST PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
15-Oct-14 04:51PMUniversal Forest posts 3Q profit AP
15-Oct-14 04:46PMUniversal Forest Products, Inc.: UFPI Q3 2014 earnings up 36.5 percent, sales up 9.5 percent; reports EPS of $0.96 Thomson Reuters ONE
Universal Forest Products, Inc., through its subsidiaries, primarily designs, manufactures, and markets wood and wood-alternative products for retail building home centers and other retailers. Its products comprise dimensional lumber, such as preserved and unpreserved lumber, and various value-added products; and engineered wood products that comprise roof and floor trusses, wall panels, engineered floor systems, I-joists, and lumber packages. The company also offers structural lumber and other products, such as roof trusses, cut and shaped lumber, plywood, particle board, and dimensional lumber for the manufactured housing industry; engineered wood components for the residential construction market; and specialty wood packaging, and components and packing materials for various industries. In addition, it provides outdoor living products, including wood composite decking, decorative balusters, post caps, and plastic lattice; lawn and garden products, such as trellises and arches, as well as offers framing services for the residential market and forming products for concrete construction. The company sells its products in the United States and internationally. Universal Forest Products, Inc. was founded in 1955 and is headquartered in Grand Rapids, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLEMAN ROBERT DExec Vice Pres ManufacturingOct 30Sale50.002,500125,00050,032Oct 31 08:29 AM
GREENE CHARLES SCOTTExec. VP MarketingJul 31Option Exercise44.861,47466,12420,032Jul 31 04:47 PM
TickerCL [NYSE, S&P 500]
CompanyColgate-Palmolive Co.
CountryUSA
IndustryPersonal Products
Market Cap60.65BEPS (ttm)2.39
P/E27.79EPS this Y-7.40%
Forward P/E20.77EPS next Y8.89%
PEG3.23EPS past 5Y5.40%
P/S3.48EPS next 5Y8.60%
P/B34.23EPS Q/Q11.70%
Dividend2.17%Sales Q/Q0.10%
Insider Own0.40%Inst Own73.80%
Insider Trans5.49%Inst Trans0.06%
Short Float0.54%EarningsOct 24/b
Analyst Recom2.70Target Price68.85
Avg Volume3.54M52W Range58.80 - 69.51
30-Oct-14 01:04PMCOLGATE PALMOLIVE CO Financials EDGAR Online Financials
28-Oct-14 01:16PMColgate Splashes Out $100m for Myanmar Toothpaste Maker at The Wall Street Journal
28-Oct-14 12:18PM[$$] Colgate Buys Myanmar Toothpaste Brand at The Wall Street Journal
27-Oct-14 06:56PMColgate-Palmolive (CL) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
24-Oct-14 01:15PMGlobal story of the consumer CNBC
24-Oct-14 12:24PMP&G Powers Down Battery Business, Colgate Q3 Mixed at Investor's Business Daily
24-Oct-14 09:48AMColgate-Palmolive (CL) Is Today's Unusual Social Activity Stock at TheStreet
24-Oct-14 08:30AMColgate profit down on weak Brazil, China demand; warns on dollar Reuters
24-Oct-14 08:30AMColgate-Palmolive Q3 Earnings Beat Estimates by a Penny Zacks
24-Oct-14 08:01AMCOLGATE PALMOLIVE CO Files SEC form 8-K, Results of Operations and Financial Condition, Costs Associated with Exit or EDGAR Online
Colgate-Palmolive Company, together with its subsidiaries, manufactures and markets consumer products worldwide. The company operates in two segments: Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as dental floss and pharmaceutical products for dentists and other oral health professionals; personal care products comprising liquid hand soaps, shower gels, bar soaps, deodorants, antiperspirants, shampoos, and conditioners; and home care products, such as dishwashing liquids, laundry and dishwashing detergents, household cleaners, oil soaps, bleaches, and fabric conditioners. The company also offers pet nutrition products for everyday nutritional needs; a range of therapeutic products to manage disease conditions; and various products with natural ingredients. Its principal trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom's of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill's Science Diet, Hill's Prescription Diet, and Hill's Ideal Balance. The company markets its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HENDRY ANDREW DChief Legal Officer &SecretaryOct 28Option Exercise36.6110,000366,100206,926Oct 31 06:00 AM
HENDRY ANDREW DChief Legal Officer &SecretaryOct 28Sale66.3210,000663,180196,926Oct 31 06:00 AM
Verduin PatriciaChief Technology OfficerOct 15Option Exercise36.613,333122,02151,247Oct 17 04:23 PM
Verduin PatriciaChief Technology OfficerOct 15Sale63.673,333212,21247,914Oct 17 04:23 PM
HENDRY ANDREW DChief Legal Officer &SecretaryOct 14Option Exercise36.6110,000366,100206,926Oct 16 04:11 PM
TickerBBY [NYSE, S&P 500]
CompanyBest Buy Co., Inc.
CountryUSA
IndustryElectronics Stores
Market Cap11.75BEPS (ttm)2.71
P/E12.41EPS this Y242.40%
Forward P/E12.96EPS next Y12.58%
PEG0.72EPS past 5Y-3.70%
P/S0.28EPS next 5Y17.30%
P/B2.59EPS Q/Q-40.60%
Dividend2.26%Sales Q/Q-4.00%
Insider Own0.90%Inst Own77.10%
Insider Trans-34.40%Inst Trans-0.19%
Short Float9.89%EarningsNov 17/b
Analyst Recom2.20Target Price34.68
Avg Volume5.44M52W Range21.75 - 43.67
31-Oct-14 08:02AMBest Buy Catching Up To Amazon Prices, Analyst Says at Investor's Business Daily
31-Oct-14 06:33AMWalmart to Start Holiday Shopping Deals on November 1 at 24/7 Wall St.
30-Oct-14 03:55PMWal-Mart mulls matching Amazons and other online rivals prices at MarketWatch
30-Oct-14 09:15AMCramer: HP's 'Sprout' amazing CNBC
29-Oct-14 07:51PMRetailers Like Lowes Are Getting a Jump on the Holidays at New York Times
29-Oct-14 03:11PMFirst Look: HP pushes into 3-D printing, Blended Reality at USA TODAY
29-Oct-14 09:55AMThe Zacks Analyst Blog Highlights: Rite Aid, CVS Health, Apple, Wal-Mart Stores and Best Buy Zacks
29-Oct-14 09:52AMMCX explains why CurrentC retailers can't use Apple Pay at USA TODAY
28-Oct-14 09:03PMApple vs. Retail - who wins mobile payment war? at USA TODAY
28-Oct-14 04:40PMChain-Store Sales Pick Up Pace Ahead Of Halloween at Investor's Business Daily
Best Buy Co., Inc. operates as a multi-national, multi-channel retailer of technology products in the United States, Canada, China, and Mexico. Its stores offer consumer electronics consisting primarily of television and home theaters; digital cameras and camcorders; DVD and Blu-ray players; portable electronics, such as MP3 devices, headphones and speakers, car stereo, navigation and satellite radio; and all related accessories. The company's stores also provide computing and mobile phone products, including notebook and desktop computers, tablets and e-readers, mobile phones and related subscription service commissions, and related accessories; entertainment products, such as video gaming hardware and software, DVDs, Blu-rays, CDs, digital downloads, and computer software; and appliances, including large and small appliances, and kitchen and bath fixtures, including faucets, sinks, toilets, and bathtubs. It also offers extended warranty service contracts, technical support, product repair, delivery, and installation services, as well as offers snacks and beverages. The company operates e-commerce operations, retail stores, and call centers; and conducts operations under various names, such as Best Buy, including BestBuy.com and BestBuy.ca; Best Buy Mobile; Five Star; Future Shop, including FutureShop.ca; Geek Squad; Magnolia Audio Video; and Pacific Sales. The company was formerly known as Sound of Music, Inc. Best Buy Co., Inc. was founded in 1966 and is headquartered in Richfield, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHULZE RICHARD M10% OwnerOct 30Sale33.18665,00022,065,0542,766,972Oct 31 06:00 AM
SCHULZE RICHARD M10% OwnerOct 29Sale32.5535,0001,139,1352,855,601Oct 31 06:00 AM
SCHULZE RICHARD M10% OwnerOct 28Sale32.7250,0001,636,1952,860,268Oct 29 05:11 PM
SCHULZE RICHARD M10% OwnerOct 27Sale33.03170,0005,615,8142,866,935Oct 29 05:11 PM
SCHULZE RICHARD M10% OwnerOct 23Sale33.21230,0007,639,1512,889,601Oct 24 04:56 PM
TickerWAL [NYSE]
CompanyWestern Alliance Bancorporation
CountryUSA
IndustryRegional - Pacific Banks
Market Cap2.29BEPS (ttm)1.60
P/E16.31EPS this Y54.70%
Forward P/E14.63EPS next Y9.59%
PEG2.04EPS past 5Y17.00%
P/S5.68EPS next 5Y8.00%
P/B2.62EPS Q/Q39.40%
Dividend-Sales Q/Q13.90%
Insider Own2.50%Inst Own75.80%
Insider Trans-0.36%Inst Trans0.28%
Short Float3.69%EarningsOct 16/a
Analyst Recom1.90Target Price28.50
Avg Volume393.44K52W Range20.56 - 26.15
30-Oct-14 04:44PMWESTERN ALLIANCE BANCORPORATION Files SEC form 10-Q, Quarterly Report EDGAR Online
30-Oct-14 08:08AMWill Western Alliance (WAL) Continue to Surge Higher? Zacks
27-Oct-14 10:34AMWeekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance ... Gurufocus
22-Oct-14 07:06AMBBCN Bancorp (BBCN) Falls: Stock Goes Down 5% Zacks
20-Oct-14 02:31PMStreet Talk: Citi cuts CLF CNBC
20-Oct-14 02:31PM[video] Street Talk: Citi cuts CLF at CNBC
20-Oct-14 08:50AMHow Will Western Alliance (WAL) Stock React Today to This Ratings Upgrade? at TheStreet
16-Oct-14 04:49PMWestern Alliance Reports Third Quarter 2014 Net Income of $40.9 million, or $0.46 Per Share Business Wire
16-Oct-14 04:42PMWESTERN ALLIANCE BANCORPORATION Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen EDGAR Online
16-Oct-14 07:07AMQ3 2014 Western Alliance Bancorporation Earnings Release - After Market Close CCBN
Western Alliance Bancorporation operates as the bank holding company for Western Alliance Bank that provides various banking and related services in Nevada, Arizona, and California. The company operates through Bank of Nevada, Western Alliance Bank, Torrey Pines Bank, and Other segments. It accepts various deposit products, including checking accounts, savings accounts, and money market accounts, as well as other deposit accounts, such as fixed-rate and fixed maturity retail certificates of deposits. The company also offers a range of loan products comprising commercial and industrial loans, which include working capital lines of credit, inventory and accounts receivable lines, mortgage warehouse lines, equipment loans and leases, and other commercial loans; commercial real estate loans that are secured by apartment buildings, professional offices, industrial facilities, retail centers, and other commercial properties; construction and land development loans; residential real estate loans; and consumer loans, such as home equity loans and lines of credit, home improvement loans, and personal lines of credit. In addition, it provides other financial services consisting of Internet banking, wire transfers, electronic bill payment, lock box services, courier, and cash management services. Further, the company offers equipment finance; and holds and manages certain non-performing loans and other real estate owned. Western Alliance Bancorporation offers its services to businesses, professional firms, real estate developers and investors, local non-profit organizations, high net worth individuals, and other consumers. As of December 31, 2013, the company operated 39 branch locations. Western Alliance Bancorporation was founded in 1994 and is headquartered in Phoenix, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NAGY M NAFEESDirectorOct 28Sale25.15100,0002,514,73014,801Oct 30 09:11 PM
GIBBONS DALEEVP and CFOOct 27Option Exercise16.509,000148,500118,431Oct 27 08:02 PM
GIBBONS DALEEVP and CFOOct 23Option Exercise16.0834,000546,600143,431Oct 27 08:02 PM
GIBBONS DALEEVP and CFOOct 23Sale24.7334,000840,837109,431Oct 27 08:02 PM
Sarver Robert GaryChairman and CEOOct 21Option Exercise10.72160,0001,715,0001,973,161Oct 23 07:24 PM
TickerEGHT [NASD]
Company8x8 Inc.
CountryUSA
IndustryDiversified Communication Services
Market Cap699.58MEPS (ttm)-0.01
P/E-EPS this Y-88.90%
Forward P/E37.42EPS next Y31.45%
PEG-EPS past 5Y20.10%
P/S4.79EPS next 5Y22.87%
P/B2.47EPS Q/Q-100.00%
Dividend-Sales Q/Q29.40%
Insider Own1.40%Inst Own65.10%
Insider Trans12.38%Inst Trans-0.75%
Short Float6.60%EarningsOct 22/a
Analyst Recom1.60Target Price10.83
Avg Volume825.98K52W Range5.69 - 11.64
31-Oct-14 08:15AM8x8 Recognized as Emerging Cloud Partner of the Year at Synergy 2015, Insights Partner Forum Business Wire
29-Oct-14 01:04PM8X8 INC /DE/ Financials EDGAR Online Financials
24-Oct-14 08:26AMWill 8x8 (EGHT) Continue to Surge Higher? Zacks
24-Oct-14 06:56AM8x8 Inc. (EGHT) in Focus: Stock Soars 14.9% Zacks
22-Oct-14 06:16PM8x8 tops Street 2Q forecasts AP
22-Oct-14 04:30PM8x8 Inc Earnings Call scheduled for 4:30 pm ET today CCBN
22-Oct-14 04:06PM8X8 INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
22-Oct-14 04:05PM8x8, Inc. Reports Second Quarter Fiscal 2015 Financial Results Business Wire
22-Oct-14 07:07AMQ2 2015 8x8 Inc Earnings Release - After Market Close CCBN
21-Oct-14 08:15AMInnovative Primary Care Provider ChenMed Deploys 8x8 HIPAA-Compliant Cloud Communications Solution at 36 Neighborhood Medical Centers Business Wire
8x8, Inc. provides unified communications and collaboration (UCC) services in the cloud for small and medium businesses, and mid-market and distributed enterprises. The company offers a suite of UCC services to in-office and mobile devices spanning cloud telephony, virtual contact center, and virtual meeting through a proprietary unified software-as-a-service platform. Its software abstracts complex networking, redundancy, security, and interconnection requirements to provide a solution for business customers. The company's software also integrates with enterprise resource planning, customer relationship management, human capital management, and other third-party application suites to provide organizations an integrated business communications and collaboration experience that is critical to operate their business. Its Infrastructure Manager software abstracts complex interconnectivity between Voice over IP, and public switched telephone network, enabling a turnkey UCC solution. The company's Integration Manager software integrates with third-party applications, allowing customers to access data while communicating with their clients or collaborating with colleagues. In addition, 8x8, Inc. sells pre-configured office phones. The company markets its services to end users through direct sales force, Website, and channel partners primarily in the United States. It serves more than 40,000 business customers with over 500,000 subscriptions. 8x8, Inc. was founded in 1987 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN BRYAN RChief Technology OfficerOct 30Option Exercise3.351,9316,4691,175,487Oct 30 09:06 PM
MARTIN BRYAN RChief Technology OfficerOct 30Sale7.751,93114,9651,173,556Oct 30 09:06 PM
MARTIN BRYAN RChief Technology OfficerOct 29Option Exercise3.3548,069161,0311,223,556Oct 30 09:06 PM
MARTIN BRYAN RChief Technology OfficerOct 29Sale7.8148,069375,6111,175,487Oct 30 09:06 PM
HECKER GUY L JRDirectorAug 08Option Exercise1.54100,000154,0001,115,815Aug 11 09:17 PM
TickerVAR [NYSE, S&P 500]
CompanyVarian Medical Systems, Inc.
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap8.67BEPS (ttm)3.84
P/E21.88EPS this Y-3.80%
Forward P/E16.92EPS next Y12.45%
PEG1.82EPS past 5Y7.60%
P/S2.84EPS next 5Y12.00%
P/B5.31EPS Q/Q-5.60%
Dividend-Sales Q/Q5.50%
Insider Own0.10%Inst Own92.10%
Insider Trans1.98%Inst Trans-0.03%
Short Float5.50%EarningsOct 22/a
Analyst Recom2.20Target Price86.39
Avg Volume716.54K52W Range71.98 - 87.85
30-Oct-14 01:17PMMidday Glance: Health Care Equipment companies AP
30-Oct-14 11:28AMEarly Glance: Health Care Equipment companies AP
29-Oct-14 06:02PMFinal Glance: Health Care Equipment companies AP
29-Oct-14 08:00AMDoctors at Innovative Cancer Institute in Miami Use New Radiosurgery System to Treat Tumor Encroaching on Patient's Spinal Cord PR Newswire
27-Oct-14 08:00AMGenesisCare Commences Cancer Treatments Using Queensland's First TrueBeam Medical Linear Accelerator for Image-Guided Radiotherapy PR Newswire
23-Oct-14 12:40PMVarian Medical Systems Misses on Q4 Earnings and Revenues Zacks
23-Oct-14 08:00AMUK's NHS Supply Chain Selects 10 TrueBeam Treatment Machines to Enable More Advanced Cancer Treatments PR Newswire
22-Oct-14 05:15PMVarian misses Street 4Q forecasts AP
22-Oct-14 04:29PMVARIAN MEDICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
22-Oct-14 04:05PMVarian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2014 PR Newswire
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy worldwide. The company's Oncology Systems segment offers linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment, and accessories; and information management, treatment planning, and image processing software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, and cancer care clinics. Its X-Ray Products segment provides X-ray imaging components to large imaging system original equipment manufacturers (OEMs) for use in radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, and industrial applications; and X-ray tubes and flat panel digital image detectors to small OEMs, independent service companies, and end-users for filmless X-ray imaging. The company also designs, manufactures, sells, and services Linatron X-ray accelerators, imaging processing software, and image detection products for security and inspection purposes, such as cargo screening at ports and borders, and nondestructive examination in various applications. In addition, it offers products and systems for delivering proton therapy; and technologies in the areas of digital X-ray imaging, volumetric and functional imaging, and improved X-ray sources, as well as technology for security and cargo screening applications. The company was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. Varian Medical Systems, Inc. was founded in 1948 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FINNEY ELISHA WExec VP and CFOOct 29Option Exercise52.8310,000528,30014,671Oct 30 08:56 PM
FINNEY ELISHA WExec VP and CFOOct 29Sale83.9510,000839,5004,671Oct 30 08:56 PM
KENNEDY KOLLEEN TSVP and Pres. Oncology Sys.Oct 27Option Exercise63.891,41590,4079,176Oct 28 09:33 PM
KENNEDY KOLLEEN TSVP and Pres. Oncology Sys.Oct 27Sale81.001,240100,4408,401Oct 28 09:33 PM
FINNEY ELISHA WExec VP and CFOOct 01Option Exercise50.6615,000759,90019,496Oct 02 08:42 PM
TickerGEVA [NASD]
CompanySynageva BioPharma Corp.
CountryUSA
IndustryBiotechnology
Market Cap2.65BEPS (ttm)-4.70
P/E-EPS this Y-78.90%
Forward P/E-EPS next Y-11.10%
PEG-EPS past 5Y-31.20%
P/S301.68EPS next 5Y-
P/B4.72EPS Q/Q-87.70%
Dividend-Sales Q/Q-32.40%
Insider Own0.20%Inst Own66.00%
Insider Trans-0.67%Inst Trans0.61%
Short Float13.98%EarningsOct 29/a
Analyst Recom1.90Target Price109.11
Avg Volume259.64K52W Range44.54 - 119.42
31-Oct-14 05:03AMSynageva BioPharma beats 3Q profit forecasts AP
30-Oct-14 04:15PMSYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
30-Oct-14 04:05PMSynageva BioPharma Reports Third Quarter 2014 Financial Results PR Newswire
29-Oct-14 07:05AMSynageva BioPharma to Present at the Nomura Biotechnology Conference PR Newswire
23-Oct-14 04:05PMSynageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting PR Newswire
21-Oct-14 04:05PMSynageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa PR Newswire
21-Oct-14 04:05PMSynageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa CNW Group
16-Oct-14 06:20AMSynageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Zacks
08-Oct-14 10:04AMSebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral Presentation During The Late-Breaking Session At The Liver Meeting® PR Newswire
22-Sep-14 05:02PMSYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib EDGAR Online
Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company's lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL), which is under Phase III clinical trials for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy for lysosomal storage diseases, known as mucopolysaccharidosis type IIIB, as well as protein therapeutic programs for rare life-threatening diseases. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOESS CARSTENSVP, Chief Financial OfficerOct 30Option Exercise9.0022,904206,22722,904Oct 30 08:21 PM
BOESS CARSTENSVP, Chief Financial OfficerOct 30Sale80.1122,9041,834,8390Oct 30 08:21 PM
BOESS CARSTENSVP, Chief Financial OfficerOct 28Option Exercise10.222,50025,5502,500Oct 30 08:21 PM
BOESS CARSTENSVP, Chief Financial OfficerOct 28Sale80.002,500200,0000Oct 30 08:21 PM
Goldberg Mark AlanEVP, Medical & Reg. StrategySep 19Option Exercise8.737906,8971,352Sep 19 05:56 PM
TickerZU [NASD]
Companyzulily, Inc.
CountryUSA
IndustryDiscount, Variety Stores
Market Cap4.43BEPS (ttm)0.04
P/E886.50EPS this Y100.00%
Forward P/E82.47EPS next Y110.78%
PEG13.00EPS past 5Y0.00%
P/S4.68EPS next 5Y68.20%
P/B17.30EPS Q/Q93.90%
Dividend-Sales Q/Q96.60%
Insider Own2.00%Inst Own90.30%
Insider Trans-1.25%Inst Trans1.66%
Short Float39.08%EarningsNov 04/a
Analyst Recom1.70Target Price44.36
Avg Volume1.21M52W Range28.75 - 73.50
28-Oct-14 09:00AMzulily Reveals Top Picks for Holiday Toys for 2014 GlobeNewswire
27-Oct-14 07:27PMzulily to Participate at RBC Technology, Internet, Media and Telecommunications Conference GlobeNewswire
21-Oct-14 04:05PMzulily, inc. Schedules Third Quarter 2014 Earnings Release and Conference Call GlobeNewswire
19-Oct-14 03:00PMAt Zulily, a small approach to big data at Fortune
17-Oct-14 12:25PMUPDATE: Canaccord Initiates Coverage On Zulily Benzinga
17-Oct-14 08:02AMCoverage initiated on zulily by Canaccord Genuity Briefing.com
03-Oct-14 02:22PM5 Stocks Poised for Breakouts at TheStreet
02-Oct-14 10:47AM[$$] Wayfair Shares Surge in Trading Debut at The Wall Street Journal
30-Sep-14 09:00AMWho's Ready to Trick or Treat? GlobeNewswire
24-Sep-14 05:50PMClaims Processor Crawford Seeks Payout with Custom Software at The Wall Street Journal
zulily, Inc. operates as an online retailer. The company operates through two segments, North America and the United Kingdom. It provides various merchandise products to moms purchasing for their children, themselves, and their homes, including children's and women's apparel comprising accessories and shoes; children's merchandise comprising infant gear, sports equipment, toys, and books; and other merchandise, such as kitchen accessories, home dcor, entertainment, electronics, and pet accessories. The company sells its products through a flash sales model. zulily, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STOLZMAN MARC DChief Financial OfficerOct 28Sale37.533,200120,0900Oct 30 08:01 PM
Twomey LoriChief MerchantSep 29Sale40.3350,0002,016,2650Oct 01 08:00 PM
Twomey LoriChief MerchantSep 24Sale38.0050,0001,900,0000Sep 26 07:37 PM
STOLZMAN MARC DChief Financial OfficerSep 24Sale37.5616,189608,1330Sep 26 07:38 PM
Twomey LoriChief MerchantSep 12Sale36.0050,0001,800,0000Sep 16 09:17 PM
TickerRVNC [NASD]
CompanyRevance Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap460.87MEPS (ttm)-1.78
P/E-EPS this Y-28.40%
Forward P/E-EPS next Y-13.40%
PEG-EPS past 5Y0.00%
P/S658.39EPS next 5Y-
P/B1.92EPS Q/Q22.50%
Dividend-Sales Q/Q-
Insider Own1.10%Inst Own73.90%
Insider Trans106.07%Inst Trans0.06%
Short Float5.24%EarningsAug 12/a
Analyst Recom2.00Target Price43.33
Avg Volume211.65K52W Range14.62 - 39.86
29-Oct-14 04:01PMRevance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014 GlobeNewswire
01-Oct-14 04:01PMRevance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines GlobeNewswire
22-Sep-14 04:10PMRevance Therapeutics Announces the Appointment of Azita Nejad as Vice President of Quality GlobeNewswire
02-Sep-14 04:10PMRevance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
29-Aug-14 04:37PMREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online
22-Aug-14 01:04PMREVANCE THERAPEUTICS, INC. Financials EDGAR Online Financials
13-Aug-14 05:23PMREVANCE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
12-Aug-14 04:15PMREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
12-Aug-14 04:10PMRevance Therapeutics Releases Second Quarter 2014 Financial Results GlobeNewswire
12-Aug-14 04:01PMRevance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. as Chief Medical Officer GlobeNewswire
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ruegg CurtisEVP R&D and Tech OperationsOct 28Option Exercise2.555001,27513,768Oct 30 08:00 PM
Ruegg CurtisEVP R&D and Tech OperationsOct 28Sale20.0050010,00013,268Oct 30 08:00 PM
Ruegg CurtisEVP R&D and Tech OperationsOct 17Option Exercise2.551,5003,82514,768Oct 21 06:38 PM
Ruegg CurtisEVP R&D and Tech OperationsOct 17Sale18.561,50027,83913,268Oct 21 06:38 PM
Waugh JacobChief Scientific OfficerSep 17Option Exercise7.7669,380538,386122,713Sep 19 07:22 PM
TickerSGMO [NASD]
CompanySangamo Biosciences Inc.
CountryUSA
IndustryBiotechnology
Market Cap811.90MEPS (ttm)-0.47
P/E-EPS this Y-14.30%
Forward P/E-EPS next Y-9.80%
PEG-EPS past 5Y4.40%
P/S26.11EPS next 5Y-
P/B3.78EPS Q/Q0.00%
Dividend-Sales Q/Q50.70%
Insider Own1.40%Inst Own76.60%
Insider Trans-6.19%Inst Trans0.53%
Short Float16.21%EarningsOct 22/a
Analyst Recom1.70Target Price25.60
Avg Volume870.98K52W Range8.93 - 24.69
30-Oct-14 08:08PM10-Q for Sangamo BioSciences, Inc. Company Spotlight
30-Oct-14 09:54AMSangamo Biosciences (SGMO) Upgraded From Sell to Hold at TheStreet
28-Oct-14 04:33PMSANGAMO BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online
22-Oct-14 06:16PMSangamo tops Street 3Q forecasts AP
22-Oct-14 05:00PMSangamo BioSciences Inc Earnings Call scheduled for 5:00 pm ET today CCBN
22-Oct-14 04:31PMSANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
22-Oct-14 04:02PMSangamo BioSciences Reports Third Quarter 2014 Financial Results PR Newswire
22-Oct-14 07:07AMQ3 2014 Sangamo BioSciences Inc Earnings Release - After Market Close CCBN
20-Oct-14 11:50AMWill Sangamo (SGMO) Incur Wider-than-Expected Q3 Loss? Zacks
16-Oct-14 07:00AMSangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014 PR Newswire
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer's disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington's disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LARSON JOHN WILLIAMDirectorOct 28Option Exercise7.2810,00072,800224,660Oct 30 08:00 PM
LARSON JOHN WILLIAMDirectorOct 28Sale12.0210,000120,153214,660Oct 30 08:00 PM
Wolff Henry WardExec VP & CFOOct 10Sale10.102,00020,200214,347Oct 14 08:00 PM
ANDO DALE GVP, Therapeutic Dev. & CMOOct 06Option Exercise4.1115,00061,650111,579Oct 08 08:00 PM
ANDO DALE GVP, Therapeutic Dev. & CMOOct 06Sale10.7215,000160,86596,579Oct 08 08:00 PM
1 2 3 4 5 6 7 8 9 10 next